Skip to main
ICUI

ICU Medical (ICUI) Stock Forecast & Price Target

ICU Medical (ICUI) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ICU Medical's positive outlook is supported by its status as a leading player in the infusion therapy market, bolstered by recent acquisitions that enhance its operational footprint and product offerings. The company's financial profile is poised for improvement, with pro forma estimates suggesting revenue growth exceeding 100 basis points, an increase in gross margin by nearly 50 basis points, and an EBITDA margin projected to surpass 20%. Additionally, ICU Medical's positioning at the forefront of a new product and pump replacement cycle indicates potential for increased investor interest and a stronger valuation multiple in the medtech sector.

Bears say

ICU Medical's financial outlook is challenged by a significant burden from its Vital Care segment, which operates at gross margins 300-400 basis points lower than the company's other segments, Consumables and Infusion Systems. The anticipated removal of approximately $35 million in annual EBITDA contribution could help lower the company's leverage, potentially bringing it below the 2x target; however, this would merely address a portion of the underlying operational inefficiencies. Additionally, the company's reliance on domestic sales, comprising over 60% of total revenue, may limit growth opportunities in a competitive global market, further exacerbating concerns regarding future profitability and market positioning.

ICU Medical (ICUI) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICU Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICU Medical (ICUI) Forecast

Analysts have given ICU Medical (ICUI) a Buy based on their latest research and market trends.

According to 3 analysts, ICU Medical (ICUI) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $175.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $175.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICU Medical (ICUI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.